Company Analysis Suven Pharmaceuticals Limited
1. Summary
Advantages
- The stock's return over the last year (71.42%) is higher than the sector average (16.78%).
- The company's current efficiency (ROE=15.86%) is higher than the sector average (ROE=3.58%)
Disadvantages
- Price (1113.4 βΉ) is higher than fair price (180.16 βΉ)
- Dividends (0%) are below the sector average (0.6379%).
- Current debt level 3.07% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Suven Pharmaceuticals Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4.1% | 0.7% | 0.7% |
| 90 days | -0.7% | -10.7% | -1.6% |
| 1 year | 71.4% | 16.8% | 6.1% |
SUVENPHAR vs Sector: Suven Pharmaceuticals Limited has outperformed the "Healthcare" sector by 54.64% over the past year.
SUVENPHAR vs Market: Suven Pharmaceuticals Limited has outperformed the market by 65.36% over the past year.
Stable price: SUVENPHAR is not significantly more volatile than the rest of the market on "Bombay Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: SUVENPHAR with weekly volatility of 1.37% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1113.4 βΉ) is higher than the fair price (180.16 βΉ).
Price is higher than fair: The current price (1113.4 βΉ) is 83.8% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (55.03) is lower than that of the sector as a whole (59.48).
P/E vs Market: The company's P/E (55.03) is higher than that of the market as a whole (44.4).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (8.06) is lower than that of the sector as a whole (8.7).
P/BV vs Market: The company's P/BV (8.06) is higher than that of the market as a whole (6.26).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (15.95) is lower than that of the sector as a whole (18.4).
P/S vs Market: The company's P/S indicator (15.95) is higher than that of the market as a whole (8.99).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (19.55) is higher than that of the sector as a whole (4.22).
EV/Ebitda vs Market: The company's EV/Ebitda (19.55) is higher than that of the market as a whole (15.13).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -1.05% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-1.05%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-17.15%).
5.4. ROE
ROE vs Sector: The company's ROE (15.86%) is higher than that of the sector as a whole (3.58%).
ROE vs Market: The company's ROE (15.86%) is higher than that of the market as a whole (-1.32%).
5.5. ROA
ROA vs Sector: The company's ROA (14.23%) is higher than that of the sector as a whole (3.38%).
ROA vs Market: The company's ROA (14.23%) is higher than that of the market as a whole (7.55%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (11.26%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (16.2%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.6379%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.75.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 3 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (49.52%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
